Receive The Newest Study Notifications

Robert Dworkin, Ph.D. Joins Lotus Clinical Research as Director, Chronic Pain Research to lead Lotus' chronic pain research programs Lotus Clinical Research, a specialty analgesic full-service CRO, has announced the addition of Robert (Bob) Dworkin, Ph.D. as Director...

Pyrrolobenzodiazepine-based antibody drug conjugate targets AXL, a receptor tyrosine kinase highly expressed in solid tumors ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of proprietary antibody drug...

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, announced today that it has dosed the first patient in a Phase 1/2 clinical trial of MRTX849, an investigational KRAS G12C inhibitor for patients with advanced solid tumors that...

In a pioneering clinical trial that will attack Alzheimer’s disease by targeting inflammation in the brain’s blood vessels, researchers at the George & Anne Ryan Institute for Neuroscience have received regulatory approval to initiate the BEACON Study. This...

Sound Pharmaceuticals (SPI) is pleased to announce that first-patient-in has been achieved in the STOP Ototoxicity Phase 2 clinical trial. This novel interventional study with SPI-1005 is aimed to prevent and treat ototoxicity in Cystic Fibrosis (CF) patients...

A research consortium recently began enrolling patients in a clinical trial examining whether fecal microbiota transplantation (FMT) by enema--putting stool from a healthy donor in the colon of a recipient--is safe and can prevent recurrent Clostridium...

A research consortium of NIH recently began enrolling patients in a clinical trial examining whether fecal microbiota transplantation (FMT) by enema—putting stool from a healthy donor in the colon of a recipient is safe and can prevent recurrent Clostridium...

Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines, announced today that the first patient has been successfully dosed in a phase I clinical trial of anti-CD47 monoclonal...

Cotinga Pharmaceuticals Inc. (TSX Venture: COT) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, today announced that it has dosed the first patient with COTI-2 in combination...

Eisai Inc. announced today the presentation of four abstracts at the 2019 Gastrointestinal Cancers Symposium (#GI19), taking place in San Francisco from January 17-19, 2019. The presentations feature the latest data from post-hoc analyses of the pivotal phase 3...

CEO Tom Equels sat down with Proactive Investors at the 11th Annual Biotech Showcase in San Francisco.  Equels says the company will begin clinical trials at the Roswell Park Comprehensive Cancer Center to start an oncology clinical study combining its...

Translational Research In Oncology (TRIO), in collaboration with Novartis and under the direction of Dennis Slamon, MD, PhD, TRIO Chairman/Executive Director and Director of Clinical Translational Research at the University of California, Los Angeles Jonsson...

Strategikon Pharma, developer of the novel clinical trial planning, budgeting, outsourcing and vendor management tool Clinical Maestro™, announced the commercial release of its Pharma (Sponsor) Edition SOURCE™ module for automating key processes in clinical...

New study suggests loosening strict comorbidity criteria would open trials to thousands of previously exempt patients Jan. 10, 2019  By Diane Mapes / Fred Hutch News Service How do you make cancer clinical trials available to more patients? A new study published today...

CYPRESS currently enrolling children aged 6-9 at clinical sites throughout the U.S. and Canada SightGlass Vision, Inc., a medical device company developing spectacle lenses to slow the progression of nearsightedness or myopia in children, today announced its...

Femasys, Inc., a medical technology company developing a platform of innovative in-office solutions for women’s healthcare today announced that the first 100 women in the BLOC pivotal clinical trial received the FemBloc® permanent contraceptive treatment. FemBloc is a...

ChemomAb, a clinical-stage biopharmaceutical company focused on the development of novel therapies for fibrotic-inflammatory diseases, announced dosing of the first patient in a Phase 1b repeated dose clinical trial with CM-101 in non-alcoholic fatty liver disease...

Advicenne (Paris:ADVIC) (Euronext: ADVIC), specializing in the development of adult and pediatric therapeutic products for the treatment of orphan renal and neurological diseases, announces today that it has received authorization from the Belgian health authority...

In an editorial published in CNS Spectrums, Jay Avasarala, MD, PhD, takes the research community to task for its lack of minority representation in Phase III clinical trials for drugs to treat Multiple Sclerosis (MS). Noting that the disease course of MS in African...

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, is updating the status of the U.S. phase 3 dry eye clinical trial (ARISE-3) and the U.S....